NEW TECH FOODS

Solis Agrosciences, a provider of specialised agricultural research services, has announced the successful completion of a series A funding round led by Cultivation Capital.

This investment aims to accelerate the company’s growth trajectory and broaden its offerings in genome editing, plant transformation and genomic sequencing.

The funding comes at a pivotal time for Solis, which has established itself as a key player in the Agtech sector, collaborating with both emerging start-ups and established multinational agricultural companies.

Kyle Welborn, general partner at Cultivation Capital, highlighted the company’s differentiated market position and rapid commercial expansion. “Solis is led by a seasoned management team and provides a differentiated offering in the agtech marketplace,” he stated, highlighting the firm’s impressive growth across a diverse customer base.

Founded to address the demand for specialied agricultural research, Solis Agrosciences operates under a capital-efficient model that allows clients to access expert talent and infrastructure without significant investment.

The company has made substantial strides since its inception, including the recent acquisition of Ferris Genomics, which has enabled it to enter the whole-genome sequencing space.

Charlie Bolten, co-founder and CEO of Solis, expressed optimism about the partnership with Cultivation Capital, noting the firm’s extensive networks and experience in the industry. “We are pleased to welcome Cultivation Capital to our strong investor syndicate,” Bolten remarked, indicating the potential for accelerated innovation and growth.

In addition to expanding its genomic services, Solis has strengthened its management team and secured a license for the Pairwise Fulcrum Platform, enhancing its capabilities in gene editing and plant transformation.

The company operates from the 39 North AgTech Innovation District in St. Louis, which serves as a hub for agricultural innovation, housing over 30 employees dedicated to providing tailored research solutions.

Solis Agrosciences has attracted a diverse range of investors, including Hermann Companies, Jim McKelvey’s Saloniki Investments, BioGenerator Ventures, and QRM Capital, among others. This broad investor base reflects confidence in Solis’s ability to deliver innovative solutions that meet the evolving needs of the agricultural sector.

With the new capital infusion, Solis is poised to continue driving advancements in Agtech, particularly in the fields of genome editing and genomic sequencing.

As the industry increasingly turns to precision agriculture and biotechnology to enhance crop yields and sustainability, Solis’s expanded capabilities are expected to play a crucial role in meeting these challenges.